This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $298,883 to Iaterion, Inc. to develop a safer menopausal hormone therapy (MHT) formula that can be used long-term to treat protracted menopausal symptoms and prevent chronic diseases like osteoporosis, diabetes, obesity, and metabolic syndrome. The project aims to create an estradiol/reprogramming ligand combination that can potentially replace the progestin component of current MHT preparations, with the goal of developing a safer long-term therapy option. The research will involve testing synthetic analogs of an original reprogramming ligand in animal models to select a lead candidate for future clinical trials. This work seeks to address the significant unmet need for long-term MHT options that can improve quality of life and health outcomes for menopausal women.